[go: up one dir, main page]

PE20181523A1 - Tratamiento de lupus nefritis usando laquinimod - Google Patents

Tratamiento de lupus nefritis usando laquinimod

Info

Publication number
PE20181523A1
PE20181523A1 PE2016000557A PE2016000557A PE20181523A1 PE 20181523 A1 PE20181523 A1 PE 20181523A1 PE 2016000557 A PE2016000557 A PE 2016000557A PE 2016000557 A PE2016000557 A PE 2016000557A PE 20181523 A1 PE20181523 A1 PE 20181523A1
Authority
PE
Peru
Prior art keywords
laquinimod
treatment
nefritis
lupus
composition
Prior art date
Application number
PE2016000557A
Other languages
English (en)
Inventor
Nora Tarcic
Asi Haviv
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20181523A1 publication Critical patent/PE20181523A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se refiere a una composicion que comprende: a) 0.5mg a 1.0 mg de laquinimod; y b) 1 g a 3 g de micofenolato mofetil. Adicionalmente, la composicion comprende: i) un esteroide tal como metilprednisolona, prednisona o prednisolona; ii) inhibidores de enzimas que convierten la angiotensina, bloqueadores del receptor de angiotensina, entre otros. Tambien se refiere a una forma de dosificacion farmaceutica. Dicha composicion es util en el tratamiento de sujetos que padecen lupus nefritis activo
PE2016000557A 2010-03-03 2011-03-02 Tratamiento de lupus nefritis usando laquinimod PE20181523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33936310P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
PE20181523A1 true PE20181523A1 (es) 2018-09-24

Family

ID=44531856

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016000557A PE20181523A1 (es) 2010-03-03 2011-03-02 Tratamiento de lupus nefritis usando laquinimod
PE2012001384A PE20130613A1 (es) 2010-03-03 2011-03-02 Tratamiento de lupus nefritis usando laquinimod

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012001384A PE20130613A1 (es) 2010-03-03 2011-03-02 Tratamiento de lupus nefritis usando laquinimod

Country Status (20)

Country Link
US (5) US8889661B2 (es)
EP (1) EP2542078B1 (es)
JP (3) JP2013521303A (es)
KR (3) KR20130006640A (es)
CN (1) CN102791130B (es)
AU (2) AU2011223692A1 (es)
BR (1) BR112012021905A2 (es)
CA (1) CA2791691A1 (es)
CL (1) CL2012002423A1 (es)
CO (1) CO6630082A2 (es)
EA (1) EA201290837A1 (es)
ES (1) ES2558556T3 (es)
IL (1) IL250357A0 (es)
MX (1) MX337614B (es)
NZ (1) NZ602510A (es)
PE (2) PE20181523A1 (es)
PH (1) PH12012501739A1 (es)
SG (2) SG183512A1 (es)
WO (1) WO2011109526A1 (es)
ZA (1) ZA201207129B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1937642T1 (sl) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
SG176840A1 (en) * 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
JP2014530821A (ja) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
CA2862865A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf.alpha. therapy
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (en) * 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
MX2015011627A (es) 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
TWI835747B (zh) * 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
KR20240155291A (ko) * 2022-03-04 2024-10-28 노파르티스 아게 루푸스 신염 치료를 위한 입타코판의 용도

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4782155A (en) 1986-03-19 1988-11-01 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
US5139878A (en) 1991-08-12 1992-08-18 Allied-Signal Inc. Multilayer film constructions
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
RS51019B (sr) 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
EP1365794A2 (en) 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
EP1517895B1 (en) 2002-06-25 2007-03-14 Merck Frosst Canada Ltd. 8-(biaryl) quinoline pde4 inhibitors
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2004251754A1 (en) 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
AU2005231467A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
JPWO2005122278A1 (ja) * 2004-06-10 2008-04-10 コニカミノルタホールディングス株式会社 有機半導体薄膜、有機半導体デバイス、有機薄膜トランジスタ及び有機エレクトロルミネッセンス素子
WO2006029036A2 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
ES2572811T3 (es) 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
KR20070105326A (ko) 2005-01-31 2007-10-30 라보라뚜와르 세로노 에스. 에이. Ｎ-하이드록시아미드 유도체 및 그것의 용도
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
SI1937642T1 (sl) 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
EP1951674B1 (en) 2005-10-26 2011-11-23 Merck Serono SA Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
PT2676967T (pt) 2006-02-28 2019-09-27 Biogen Ma Inc Métodos para tratamento de doenças inflamatórias e autoimunes com natalizumab
WO2007100763A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
CA2644110A1 (en) 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2645322A1 (en) * 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
US20080090897A1 (en) 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
MX2009001788A (es) 2006-08-17 2009-09-23 Univ Chicago Tratamiento de enfermedades inflamatorias.
KR20090104041A (ko) 2006-12-19 2009-10-05 메리맥 파마슈티컬즈, 인크. 다발성 경화증을 치료하기 위한 α페토프로테인 및 면역조절제의 병용투여
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
SI2139517T1 (sl) * 2007-03-27 2013-09-30 Zymogenetics, Inc. Kombinacija inhibicije BLyS in mikofenolat mofetila za zdravljenje avtoimunske bolezni
JP5468001B2 (ja) 2007-07-11 2014-04-09 メディシノバ，インコーポレーテッド イブジラストを含む進行性神経変性疾患の処置用医薬組成物
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
US8552194B2 (en) 2008-04-28 2013-10-08 Actavis Group Ptc Ehf Process for preparing quinoline-3-carboxamide derivatives
US8354428B2 (en) * 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
UA104005C2 (ru) 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
SG176840A1 (en) 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
ES2601819T3 (es) 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Tratamiento de la artritis lúpica usando laquinimod
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
EP2590653A4 (en) 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
JP5396349B2 (ja) * 2010-08-10 2014-01-22 日立ビークルエナジー株式会社 二次電池
US20120142730A1 (en) 2010-12-07 2012-06-07 Nora Tarcic Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
CN103781354A (zh) 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
CA2843432A1 (en) 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Also Published As

Publication number Publication date
ZA201207129B (en) 2014-06-25
CL2012002423A1 (es) 2012-12-21
MX2012010070A (es) 2012-10-03
EA201290837A1 (ru) 2013-05-30
IL250357A0 (en) 2017-03-30
HK1177878A1 (zh) 2013-08-30
PE20130613A1 (es) 2013-06-23
EP2542078A4 (en) 2013-07-10
US20180140594A1 (en) 2018-05-24
CA2791691A1 (en) 2011-09-09
ES2558556T3 (es) 2016-02-05
CN102791130B (zh) 2015-02-25
KR20160129093A (ko) 2016-11-08
PH12012501739A1 (en) 2017-08-23
SG183512A1 (en) 2012-09-27
US20170258780A1 (en) 2017-09-14
AU2016204466A1 (en) 2016-07-21
AU2011223692A1 (en) 2012-10-25
CN102791130A (zh) 2012-11-21
CO6630082A2 (es) 2013-03-01
US20150038508A1 (en) 2015-02-05
US8889661B2 (en) 2014-11-18
US20110218179A1 (en) 2011-09-08
NZ602510A (en) 2014-11-28
EP2542078A1 (en) 2013-01-09
US20170368053A1 (en) 2017-12-28
KR20150135552A (ko) 2015-12-02
KR20130006640A (ko) 2013-01-17
SG10201501535UA (en) 2015-04-29
WO2011109526A1 (en) 2011-09-09
BR112012021905A2 (pt) 2015-09-29
MX337614B (es) 2016-03-10
EP2542078B1 (en) 2015-10-07
JP2016128464A (ja) 2016-07-14
JP2013521303A (ja) 2013-06-10
JP2017165740A (ja) 2017-09-21

Similar Documents

Publication Publication Date Title
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
IN2012DN02735A (es)
IN2012DN00754A (es)
JP2016053040A5 (es)
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX2013004061A (es) Analogos de ciclosporina.
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
ECSP11011459A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
EA201791009A1 (ru) Композиции, содержащие циклоспорин
MX2013004062A (es) Analogos de ciclosporina.
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MX378056B (es) Composiciones de cuidado oral.
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w

Legal Events

Date Code Title Description
FD Application declared void or lapsed